In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 7.27 a new company low.

Within Major Pharmaceutical Preparations industry Braveheart Bio, Inc. booked the highest Quick Ratio than Braveheart Bio in the third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from to 431.

Explain Quick Ratio?
How much Cash & cash equivalents BRVE�s has?
What are BRVE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BRVE/financial-strength

https://api.csimarket.com/api/v1/companies/BRVE/fundamentals

https://api.csimarket.com/api/v1/companies/BRVE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BRVE Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Dec 31 2025) Q2	Q3	Q2
Y / Y Current Liabilities Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	7.27	Subscribe	Subscribe	Subscribe	Subscribe
BRVE's Total Ranking	# 431	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	84.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-1.25 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 0
Healthcare Sector	# 0
Overall Market	# 0

Quick Ratio Statistics
High	Average	Low
17.01	12.61	7.27
(Dec 31 2025)		(Sep 30 2026)

Financial Statements
Braveheart Bio's Current Liabilities	$ 17 Millions	Visit BRVE's Balance sheet
Braveheart Bio's Cash & cash equivalent	$ 121 Millions	Visit BRVE's Balance sheet
Source of BRVE's Sales		Visit BRVE's Sales by Geography

Cumulative Braveheart Bio's Quick Ratio

BRVE's Quick Ratio for the trailling 12 Months

BRVE Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Dec 31 2025) 12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	10.76	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 431	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	116.59 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	57.21 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BRVE Financial Strength Comparisons >> Go to Compare BRVE Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $16.67 millions, cumulative Quick Ratio decreased to 10.76 below the Braveheart Bio, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry BRVE achieved the highest Quick Ratio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents BRVE�s has?
What are BRVE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 0
Healthcare Sector	# 0
Within the Market	# 431

trailing twelve months Quick Ratio Statistics
High	Average	Low
17.01	12.61	7.27
(Dec 31 2025)		(Sep 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Monopar Therapeutics Inc	17.65	$ 52.634 Millions	$ 2.982 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Ensysce Biosciences Inc	13.56	$ 29.671 Millions	$ 2.189 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Erasca Inc	13.10	$ 643.696 Millions	$ 49.122 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Assembly Biosciences Inc	12.61	$ 314.262 Millions	$ 24.921 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions

Date modified: 2026-11-11T13:35:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.